Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk

Clinical Pharmacology and Therapeutics - United States
doi 10.1002/cpt.1436